Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Plasmacytoid dendritic cells in multiple sclerosis: chemokine and chemokine receptor modulation by interferon-beta.

Literature DB >> 20621365

Plasmacytoid dendritic cells in multiple sclerosis: chemokine and chemokine receptor modulation by interferon-beta.

Latt Latt Aung¹, Patricia Fitzgerald-Bocarsly, Suhayl Dhib-Jalbut, Konstantin Balashov.

Abstract

Plasmacytoid dendritic cells (pDCs) are present in peripheral blood, leptomeninges and demyelinating lesions in patients with multiple sclerosis (MS). The ability of pDCs to produce chemokines and express the chemokine receptor CCR7 in MS is not known. We studied pDCs in MS patients and healthy subjects. The ability of pDCs to up-regulate CCR7 was significantly increased in untreated MS patients as compared to healthy subjects. IFN-beta treatment significantly inhibited TLR9 agonist-specific secretion of chemokines, which are ligands for CCR5-positive Th1 cells (CCL3, CCL4, and CCL5), and impaired TLR9 agonist-induced up-regulation of CCR7 and IFN-alpha in MS patients. This finding represents a new immunomodulatory effect of IFN-beta in patients with multiple sclerosis.

Entities: Chemical Disease Gene Mutation Species

Mesh：

Substances：

Year: 2010 PMID： 20621365 PMCID： PMC2937086 DOI： 10.1016/j.jneuroim.2010.06.008

Source DB: PubMed Journal: J Neuroimmunol ISSN： 0165-5728 Impact factor: 3.478

65 in total

Review 1. Multiple sclerosis.

Authors: Alastair Compston; Alasdair Coles
Journal: Lancet Date: 2002-04-06 Impact factor: 79.321

2. Cutting edge: selective usage of chemokine receptors by plasmacytoid dendritic cells.

Authors: G Penna; S Sozzani; L Adorini
Journal: J Immunol Date: 2001-08-15 Impact factor: 5.422

3. Elevated expression of CCR5 by myeloid (CD11c+) blood dendritic cells in multiple sclerosis and acute optic neuritis.

Authors: M Pashenkov; N Teleshova; M Kouwenhoven; V Kostulas; Y-M Huang; M Soderstrom; H Link
Journal: Clin Exp Immunol Date: 2002-03 Impact factor: 4.330

4. Activation of APCs through CD40 or Toll-like receptor 9 overcomes tolerance and precipitates autoimmune disease.

Authors: Hiroshi T Ichikawa; Lucas P Williams; Benjamin M Segal
Journal: J Immunol Date: 2002-09-01 Impact factor: 5.422

5. Immunization and MS: a summary of published evidence and recommendations.

Authors: Olivier T Rutschmann; Douglas C McCrory; David B Matchar
Journal: Neurology Date: 2002-12-24 Impact factor: 9.910

Review 6. Differential migration behavior and chemokine production by myeloid and plasmacytoid dendritic cells.

Authors: Giuseppe Penna; Marisa Vulcano; Silvano Sozzani; Luciano Adorini
Journal: Hum Immunol Date: 2002-12 Impact factor: 2.850

7. Cutting edge: differential chemokine production by myeloid and plasmacytoid dendritic cells.

Authors: Giuseppe Penna; Marisa Vulcano; Andrea Roncari; Fabio Facchetti; Silvano Sozzani; Luciano Adorini
Journal: J Immunol Date: 2002-12-15 Impact factor: 5.422

8. CCR1+/CCR5+ mononuclear phagocytes accumulate in the central nervous system of patients with multiple sclerosis.

Authors: C Trebst; T L Sørensen; P Kivisäkk; M K Cathcart; J Hesselgesser; R Horuk; F Sellebjerg; H Lassmann; R M Ransohoff
Journal: Am J Pathol Date: 2001-11 Impact factor: 4.307

9. Two subsets of dendritic cells are present in human cerebrospinal fluid.

Authors: M Pashenkov; Y M Huang; V Kostulas; M Haglund; M Söderström; H Link
Journal: Brain Date: 2001-03 Impact factor: 13.501

10. Lymphoid chemokines CCL19 and CCL21 are expressed in the central nervous system during experimental autoimmune encephalomyelitis: implications for the maintenance of chronic neuroinflammation.

Authors: Sandra Columba-Cabezas; Barbara Serafini; Elena Ambrosini; Francesca Aloisi
Journal: Brain Pathol Date: 2003-01 Impact factor: 6.508

16 in total

Plasmacytoid dendritic cells in multiple sclerosis: chemokine and chemokine receptor modulation by interferon-beta.

Review 1. Multiple sclerosis.

2. Cutting edge: selective usage of chemokine receptors by plasmacytoid dendritic cells.

3. Elevated expression of CCR5 by myeloid (CD11c+) blood dendritic cells in multiple sclerosis and acute optic neuritis.

4. Activation of APCs through CD40 or Toll-like receptor 9 overcomes tolerance and precipitates autoimmune disease.

5. Immunization and MS: a summary of published evidence and recommendations.

Review 6. Differential migration behavior and chemokine production by myeloid and plasmacytoid dendritic cells.

7. Cutting edge: differential chemokine production by myeloid and plasmacytoid dendritic cells.

8. CCR1+/CCR5+ mononuclear phagocytes accumulate in the central nervous system of patients with multiple sclerosis.

9. Two subsets of dendritic cells are present in human cerebrospinal fluid.

10. Lymphoid chemokines CCL19 and CCL21 are expressed in the central nervous system during experimental autoimmune encephalomyelitis: implications for the maintenance of chronic neuroinflammation.

1. Multiple sclerosis-linked and interferon-beta-regulated gene expression in plasmacytoid dendritic cells.

Review 2. Dendritic cell migration in health and disease.

3. Resident plasmacytoid dendritic cells patrol vessels in the naïve limbus and conjunctiva.

Review 4. Plasmacytoid dendritic cells and immunotherapy in multiple sclerosis.

5. Role of toll-like receptors in multiple sclerosis.

6. Engineering release kinetics with polyelectrolyte multilayers to modulate TLR signaling and promote immune tolerance.

7. Design of Polyelectrolyte Multilayers to Promote Immunological Tolerance.

Review 8. Dendritic cells as therapeutic targets in neuroinflammation.

Review 9. Close Encounters of the First Kind: Innate Sensors and Multiple Sclerosis.

10. A systems medicine approach reveals disordered immune system and lipid metabolism in multiple sclerosis patients.